scholarly journals Invasive Aspergillosis in Liver Transplant Recipients: Outcome Comparison of Therapy with Amphotericin B Lipid Complex and a Historical Cohort Treated with Conventional Amphotericin B

2003 ◽  
Vol 37 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Peter K. Linden ◽  
Kim Coley ◽  
Paolo Fontes ◽  
John J. Fung ◽  
Shimon Kusne
Keyword(s):  
Liver Transplant ◽  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Transplant Recipients ◽  
Lipid Complex ◽  
Historical Cohort ◽  
Outcome Comparison ◽  
Amphotericin B Lipid Complex ◽  
Liver Transplant Recipients

Apparent lack of cross-reactivity for infusion-related reactions between two forms of lipid-based amphotericin B

2013 ◽  
Vol 70 (12) ◽  
pp. 1047-1051 ◽  
Author(s):  
Mitchell S. Buckley ◽  
Clint S. Anderson ◽  
Shardool A. Patel ◽  
Melanie J. Yerondopoulos ◽  
Laura M. Wicks ◽  
...  
Keyword(s):  
Invasive Aspergillosis ◽  
Amphotericin B ◽  
Adverse Reactions ◽  
Cross Reactivity ◽  
Alternative Formulation ◽  
Lipid Complex ◽  
Apparent Lack ◽  
Course Of Action ◽  
Amphotericin B Lipid Complex ◽  
Alternative Lipid

Abstract Purpose The case of a patient who experienced probable infusion-related reactions to amphotericin B lipid complex (ABLC) but tolerated continued amphotericin B therapy after a switch to an alternative lipid-based formulation is reported. Summary A 28-year-old immunocompromised man with pneumonia, respiratory failure, and neutropenic fever was initiated on ABLC and other antibiotics for suspected invasive aspergillosis. Due to the patient’s deteriorating renal function, the use of amphotericin B was deemed preferable to the standard therapy for invasive aspergillosis (voriconazole) even though he had experienced likely infusion-related reactions to ABLC on two prior occasions. During the infusion of ABLC, significant increases in the man’s temperature, respiratory rate, systolic blood pressure, and heart rate were observed. Although those symptoms were suspected to be infusion related, it was decided that continuing amphotericin B therapy with an alternative lipid-based form of the drug was the best course of action. After the patient was switched to liposomal amphotericin B one day later, no further infusion-related adverse reactions were noted for the duration of therapy. While this case suggests that adverse reactions to one type of amphotericin B might not occur with the use of an alternative formulation, further research is needed to better define the potential for cross-reactivity among various forms of amphotericin B and related safe-infusion practices. Conclusion A patient with invasive aspergillosis who experienced likely infusion- related reactions to ABLC was able to tolerate continued amphotericin B therapy after a switch to the liposomal formulation.

Sign in / Sign up

Export Citation Format

Share Document